Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Not all insulin secretagogues sensitize pancreatic islets to recombinant human interleukin 1 beta

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of thyrotropin-releasing hormone on regional cerebral blood flow in man

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Systemic TNFα correlates with residual β-cell function in children and adolescents newly diagnosed with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. High prevalence of disordered eating behavior in Danish children and adolescents with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Decreased markers of bone turnover in children and adolescents with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Unaffected bone mineral density in Danish children and adolescents with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The purpose of this study was to test the influence of different insulin secretagogues on interleukin 1 beta mediated injury to isolated rat pancreatic islets. Islets were exposed to interleukin 1 beta for 6 days. During exposure, beta-cells were stimulated with glucose (11 mmol/l vs 3.3 mmol/l) or with non-nutrients as tolbutamide (250 mumols/l), iso-butyl 1-methyl-xanthine (50 mumols/l), or glucagon (10 mg/l). At 3.3 mmol/l of glucose, 60,000 U/l of interleukin 1 beta caused an inhibition of medium insulin accumulation to 62 +/- 5% of control from 48 h to 6 days of exposure, whereas islet DNA content was unaffected. At 11 mmol/l of glucose, interleukin 1 beta dose-dependently decreased medium insulin accumulation (e.g. 60,000 U/l of interleukin 1 beta, 12 +/- 3% of control) and islet content of DNA (60,000 U/l of interleukin 1 beta, 60 +/- 8% of control). During beta-cell stimulation with tolbutamide, interleukin 1 beta caused inhibition of insulin accumulation to 36 +/- 9% of control. In contrast, on islets stimulated with iso-butyl 1-methyl-xanthine or glucagon, the effects of interleukin 1 beta were equivalent to those on non-stimulated islets. These differences were paralleled by differences in the interleukin 1 beta effect on islet morphology. In conclusion, high beta-cell activity (as measured by islet insulin release) may increase islet susceptibility to interleukin 1 beta, however, depending upon the intracellular pathway through which insulin secretion is activated.

OriginalsprogEngelsk
TidsskriftActa Endocrinologica (Copenh)
Vol/bind123
Udgave nummer4
Sider (fra-til)445-52
Antal sider8
ISSN0001-5598
StatusUdgivet - okt. 1990
Eksternt udgivetJa

ID: 46523306